Percutaneous Coronary Intervention After Fibrinolysis A Multiple Meta-Analyses Approach According to the Type of Strategy by Collet, Jean-Philippe et al.
FP
A
J
M
P
F
r
f
fi
5
t
s
l
P
f
t
t
c
a
O
L
2
Journal of the American College of Cardiology Vol. 48, No. 7, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
POCUS ISSUE: CARDIAC INTERVENTION
ercutaneous Coronary Intervention After Fibrinolysis
Multiple Meta-Analyses Approach According to the Type of Strategy
ean-Philippe Collet, MD, PHD,* Gilles Montalescot, MD, PHD,*
ichel Le May, MD,† Maria Borentain, MD,* Anthony Gershlick, MD‡
aris, France; Ottawa, Ontario, Canada; and Leicester, United Kingdom
OBJECTIVES We performed a meta-analysis of randomized trials that enrolled ST-segment elevation
myocardial infarction patients treated with fibrinolysis to assess the potential benefits of: 1)
rescue percutaneous coronary intervention (PCI) versus no PCI; 2) systematic and early (24
h) PCI versus delayed or ischemia-guided PCI; 3) fibrinolysis-facilitated PCI versus primary
PCI alone.
BACKGROUND The impact of PCI strategies after fibrinolysis on mortality or reinfarction remains to be
established.
METHODS The meta-analysis was performed using the odds ratio (OR) as the parameter of efficacy with
a random effect model. Fifteen randomized trials (5,253 patients) were selected. The primary
end point was mortality or the combined end point of death or reinfarction.
RESULTS Rescue PCI for failed fibrinolysis reduced mortality (6.9% vs. 10.7%) (OR, 0.63; 95%
confidence interval [CI], 0.39 to 0.99; p 0.055) and the rate of death or reinfarction (10.8%
vs. 16.8%) (OR, 0.60; 95% CI, 0.41 to 0.89; p  0.012) compared with a conservative
approach. Systematic and early PCI performed during the “stent era” led to a nonsignificant
reduction in mortality compared with delayed or ischemia-guided PCI (3.8% vs. 6.7%) (OR,
0.56; 95% CI, 0.29 to 1.05; p  0.07) and to a 2-fold reduction in the rate of death or
reinfarction (7.5% vs. 13.2%) (OR, 0.53; 95% CI, 0.33 to 0.83; p  0.0067). This benefit
contrasted with a nonsignificant increase in the rate of both mortality (5.5% vs. 3.9%, p 
0.33) or death or reinfarction (9.6% vs. 5.7%, p  0.06) observed in the “balloon era.”
Fibrinolysis-facilitated PCI was associated with more reinfarction as compared with primary
PCI alone (5.0% vs. 3.0%) (OR, 1.68; 95% CI, 1.12 to 2.51; p  0.013) without significant
impact on mortality (OR, 1.30; 95% CI, 0.92 to 1.83; p  0.13).
CONCLUSIONS Our findings support rescue PCI and systematic and early PCI after fibrinolysis. However, the
current data do not support fibrinolysis-facilitated PCI in lieu of primary PCI alone. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.064Coll Cardiol 2006;48:1326–35) © 2006 by the American College of Cardiology Foundation
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cibrinolytic therapy became the first effective treatment to
educe mortality in ST-segment elevation myocardial in-
arction (STEMI) (1). Accessible to virtually all patients,
brinolysis fails, however, to reopen occluded arteries in
0% of cases.
See page 1336
Primary percutaneous coronary intervention (PCI) is now
he reperfusion strategy of choice in STEMI because it is
uperior to fibrinolysis in reducing the rate of death regard-
ess of time from symptom onset (2). Even if transfer to a
CI center is necessary, primary PCI performed in a timely
ashion remains superior to fibrinolysis (3). However, access
o a catheterization laboratory within an acceptable time is
he main limitation of this strategy (4–6). Therefore, the
ombination of fibrinolysis and mechanical reperfusion
ppears logical. Obviously, there is a need to assess the role
From the *Pitié-Salpêtrière University Hospital, Paris, France; †University of
ttawa Heart Institute, Ottawa, Ontario, Canada; and ‡University Hospital of
eicester, Leicester, United Kingdom.p
Manuscript received December 13, 2005; revised manuscript received February 27,
006, accepted March 16, 2006.f PCI done at different time intervals after fibrinolysis and
hether the approach should be selective or systematic.
Currently, there are 3 different time-related PCI strate-
ies that can be applied after initiation of fibrinolysis.
escue PCI is attempted when there is failure of fibrinoly-
is, usually documented by ongoing chest pain and/or
ersistent ST-segment elevation at 60 to 90 min after
nitiation of fibrinolytic therapy. The second strategy consists
f a systematic and early (24 h) PCI approach after admin-
stration of fibrinolysis irrespective of the latter’s success rather
han the traditional conservative approach of delayed and/or
schemia-guided PCI. The third strategy of fibrinolysis-
acilitated PCI involves the administration of fibrinolytic
herapy to improve flow in the infarct-related artery before
nd/or during the transfer for PCI.
We have performed 3 separate meta-analyses with all
tudies available to assess mortality and reinfarction benefits
f each strategy.
ETHODS
rial selection. We conducted a MEDLINE and Co-
hrane Controlled Trials Register search of published re-
orts completed by a more systematic approach using the
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October 3, 2006:1326–35 PCI Strategies After Fibrinolysisobinson and Dickersin methodology (7) to identify all
andomized trials published in the last 20 years that
ompared: 1) rescue PCI versus no PCI after failed
brinolysis; 2) systematic and early PCI irrespective of
brinolysis success versus delayed and/or ischemia-guided
CI; 3) fibrinolysis-facilitated PCI versus primary PCI. We
sed the following keywords: “acute myocardial infarction,”
fibrinolysis,” “thrombolysis,” “failed fibrinolysis,” “failed
hrombolysis,” “rescue angioplasty,” “primary coronary an-
ioplasty,” and “meta-analysis.” In addition, we searched for
apers presented at major cardiac conferences. Finally, text
nd journal article bibliographies were hand searched. Con-
emporary trials referred to trials performed during the
stent era” with a stenting rate 25% as opposed to trials
erformed during the “balloon era.”
tudy objective and design. Our objectives were to assess
he relative benefits of the following different strategies in
atients with STEMI: 1) for failed fibrinolysis: rescue PCI
ersus a conservative treatment; 2) after fibrinolysis regard-
ess of success: systematic and early (within 24 h) PCI versus
elayed and/or ischemia-guided PCI; and 3) fibrinolysis-
acilitated PCI versus primary PCI alone.
Definitions of the characteristics of the trials selected for
he meta-analysis, including definitions of STEMI, fibrino-
ysis failure, and PCI delays, were those of the trials
oncerned. It was recognized that there would be heteroge-
eity in the studies such as symptom onset to fibrinolysis,
nd fibrinolysis to PCI, as well as adjunctive pharmacologic
gents and devices used. To minimize this issue, we selected
nly studies that included patients with STEMI 12 h of
ymptom onset and studies that provided data on death and
einfarction. In addition, “balloon era” studies and “stent
ra” studies were analyzed separately to assess whether the
mprovement of PCI techniques may have improved the
utcomes of the post-fibrinolysis PCI strategies.
For rescue PCI, we restricted our analysis to studies that
ttempted to perform PCI 12 h after failed fibrinolytic
herapy. There were no exclusion criteria regarding the type of
brinolytic agent used and the type of PCI. Failed fibrinolysis
as defined: 1) clinically as failure of ST-segment reso-
ution with persistent chest pain; or 2) angiographically as
hrombolysis In Myocardial Infarction (TIMI) flow grade
to 1 within the infarct-related artery. In that respect, the
ESCUE (Randomized Evaluation of Salvage Angioplasty
Abbreviations and Acronyms
CI  confidence interval
GP  glycoprotein
OR  odds ratio
PCI  percutaneous coronary intervention
REACT  Rescue Angioplasty Versus Conservative
Therapy or Repeat Thrombolysis Trial
STEMI  ST-segment elevation myocardial infarctionith Combined Utilization of Endpoints) II study was vxcluded because only patients with TIMI flow grade 2 were
onsidered for randomization (8).
Systematic and early intervention after fibrinolytic treat-
ent was defined as catheterization performed 24 h of
brinolytic therapy irrespective of its success. We selected
rials with fibrinolysis being the initial mode of reperfusion
n all patients with further randomization to early and system-
tic catheterization 24 h or delayed ischemic-driven revas-
ularization. We excluded studies with a systematic invasive
trategy delayed by 24 h after fibrinolysis (6,9–13).
tudies that compared delayed PCI to no PCI after fibri-
olysis were also excluded, being considered as obsolete
trategies (14–18). There were no exclusion criteria regard-
ng the type of fibrinolytic agent and the type of PCI.
When evaluating fibrinolysis-facilitated PCI, we selected
tudies with PCI being the main mode of reperfusion in all
atients, with a randomization process evaluating fibrinoly-
is as facilitating agent during transfer to the catheterization
aboratory. Studies using combined-treatments facilitation
ith reduced dose of lytics  full dose of glycoprotein (GP)
Ib/IIIa inhibitors were not considered. The delay between
nitiation of fibrinolysis and PCI had to be 6 h. Studies
hat did not report death and reinfarction rates were
xcluded (19).
nd points and definitions. The primary end point was
ortality. The combined end point of death or reinfarction
as also examined. When complete data were not available,
he principal investigators of the studies were contacted.
nd points were evaluated at the longest available follow-
p. The definition of reinfarction was different in each trial,
nd thus we decided to use the trial-specific definition of
einfarction. Major bleeding, primarily a safety end point,
as defined differently among trials. Again, the trial-specific
efinition was retained.
ata management. Two authors (J-P.C., M.B.) indepen-
ently reviewed abstracts and published manuscripts. A
otal of 15 nonoverlapping studies met the inclusion criteria.
ndependent data extraction was performed by the 2 review-
rs and confirmed by consensus.
ata analysis. The results from each trial were those
btained on an intention-to-treat basis. The meta-analysis
as performed using the odds ratio (OR) as the parameter
f efficacy with a random effect model (Mantel-Haenszel),
ith appropriate tests for association and heterogeneity.
he p value for significance of association and heterogeneity
ests was set at 0.1 as suggested (20). Meta-analysis calcu-
ation (association test) and heterogeneity were performed
ith the EasyMa software (INSERM, University Claude
ernard, Lyon, France) (21).
ESULTS
earch results. A total of 28 studies corresponding to a
otal of 11,206 patients were identified as potentially rele-
ant to the 3 pre-specified questions (Fig. 1). We excluded
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PCI Strategies After Fibrinolysis October 3, 2006:1326–35total of 11 randomized trials according to the inclusion
nd exclusion criteria and 2 nonrandomized trials.
escue angioplasty after failed fibrinolysis. Five random-
zed trials comparing rescue PCI to a conservative approach
fter failed fibrinolysis were identified, representing a total
f 920 patients. The trial names, acronyms, patient character-
stics, and details of the study groups are shown in Table 1.
escue PCI was performed 12 h of symptom onset in all
rials. Stents and GP IIb/IIIa receptor antagonists were used
nly in the 2 most recent trials (22–24). Patients who were
eadministered fibrinolytic therapy after failed fibrinolysis were
ot considered in the present meta-analysis because our pri-
ary attempt was to compare rescue PCI with a conservative
trategy including no reperfusion therapies of any kind.
Reports on mortality and reinfarction rates were available
or the in-hospital period in 1 trial (25), at 30 days in 3 trials
22–24,26), at 6 weeks in 1 trial (27), and at 6 months and
year in the 2 stent era studies (22,23). The death rate was
Figure 1. Meta-analysis profile. PC.8% (81of 920) within the first month and 10.4% (96 of T20) at the longest follow-up available. It was similar across
he different trials.
Within the 30 days of follow-up, there was a nonsignif-
cant reduction in mortality in the rescue PCI group as
ompared with the group treated conservatively in either the
balloon era” studies and in the “stent era” studies (Fig. 2A).
ombining all the trials, there was a 37% reduction in
ortality in the rescue PCI group as compared with the
roup treated conservatively (p  0.055) (Fig. 2A). At
ongest-term follow-up (up to 1 year), there was a nonsig-
ificant reduction in the rate of death in the rescue group as
ompared with the conservative group (41 of 462 vs. 55 of
58) (OR, 0.69; 95% confidence interval [CI], 0.41 to 1.57;
 0.16).
There was also a reduction of the combined end point of
eath or reinfarction in favor of rescue PCI at both
hort-term follow-up (p  0.012) (Fig. 2B) and long-term
ollow-up (OR, 0.60; 95% CI, 0.39 to 0.92; p  0.019).
ercutaneous coronary intervention.he beneficial effect rescue PCI regarding the occurrence of
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October 3, 2006:1326–35 PCI Strategies After Fibrinolysiseath or myocardial infarction was only observed in the
stent era” trials but remained nonsignificant in the “balloon
ra” trials although there was always a favorable trend.
Rescue PCI was associated with major bleeding in 11.9%
44 of 368) of patients as compared with 1.3% (5 of 373) in
he group treated conservatively (OR, 9.05; 95% CI, 3.71 to
2.06; p  0.001). In patients treated with rescue PCI,
ajor bleeding was associated with the femoral sheath used
or catheterization in 82% (22 of 27), and none were fatal.
here was 1 retroperitoneal bleed (transfused) and 4 gas-
rointestinal bleeds (2 transfused) without sequelae. Of
igure 2. (A) Odds ratios for death with rescue angioplasty versus
onservative approach within the first 30 days after randomization. The
ncidence of death rate was lower in the rescue group than in the
onservative group. Overall odds ratio 0.63; 95% confidence interval (CI),
.39 to 1.01; p  0.055. The analysis for heterogeneity was nonsignificant
p  0.53). (B) Odds ratios for death or reinfarction with rescue
ngioplasty versus conservative approach within the first 30 days of
andomization. The incidence of death or reinfarction was lower in the
escue group than in the conservative group. Overall odds ratio 0.60; 95%
I, 0.41 to 0.89; p  0.012. The analysis for heterogeneity was nonsig-
ificant (p  0.44). LIMI  LImburg Myocardial Infarction trial; MA 
eta-analysis; MERLIN  Middlesbrough Early Revascularisation to
imit INfarction; PCI  percutaneous coronary intervention; PTCA 
ercutaneous transluminal coronary angioplasty; REACT  Rescue An-
ioplasty Versus Conservative Therapy or Repeat Thrombolysis Trial;
ESCUE  Randomized Evaluation of Salvage Angioplasty with Com-bined Utilization of Endpoints.Ta
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PCI Strategies After Fibrinolysis October 3, 2006:1326–35nterest, 69% of these rescue PCI patients had received
bciximab compared with 43% overall.
All the analyses for heterogeneity were nonsignificant for
ll the end points in the preceding text.
ystematic and early angioplasty after fibrinolysis. Six
andomized trials were identified for the comparison of a
ystematic and early catheterization versus delayed and/or
schemia-guided catheterization after fibrinolysis (n  1,508
atients) (Table 2). Three of these trials were performed in the
arly days of mechanical intervention (13,28,29).
Enrollment criteria and trial designs were similar in all
tudies (Table 2). The majority of patients were treated with
fibrin-specific fibrinolytic agent. Time from symptom
nset to administration of fibrinolytic therapy was compa-
able in all trials and always 12 h. After initiation of
brinolysis, systematic and early PCI was performed 6 h
n 5 studies (13,28–31). In the stent era studies, PCI took
lace at least 90 min after fibrinolysis initiation in all trials
nd 3 h in the 2 trials (Table 2).
The pharmacologic approaches were different between
rials of the “balloon era” (13,28,29) and those of the “stent
ra” (30–32). During the “balloon era,” aspirin was not
iven immediately to all patients, and thienopyridines were
ot available. In the stent era, aspirin and thienopyridines
ere given to 80% of patients treated with early PCI, and
P IIb/IIIa receptor antagonists were used in 10% to 30%
f these patients.
Mortality and reinfarction data were available within the
rst 6 weeks in all studies, at 6 months in 2 studies (30,31),
nd at 1 year in 1 study (32). The composite end point of
eath or reinfarction was consistent throughout the studies
ith few differences between trials. Data on major bleeding
ere available only in contemporary trials. At late follow-
p, the death or reinfarction rate in the control arm
conservative approach) did not differ between trials of the
balloon era” (7.8%) and trials of the “stent era” (10.1%).
The systematic and early PCI strategy in the “stent era”
n  832) was associated with a 44% reduction of death
p  0.07); however, it was not significant (Fig. 3A). This
enefit was obtained without significant excess of major
leeding (OR, 1.18; 95% CI, 0.60 to 2.30; p  0.64). The
ate of death or reinfarction in the contemporary trials was
-fold lower in the systematic and early PCI group than in
he delayed or ischemia-guided PCI group (7.5% vs. 13.2%,
espectively, p  0.0067). In contrast, the meta-analysis of
rials done in the “balloon era” (n  675) showed a
onsignificant 44% increase of mortality in the systematic
nd early PCI group as compared with the delayed or
schemia-guided PCI group (Fig. 3A). Similarly, there was
76% increase in death or reinfarction in the systematic and
arly PCI group as compared with the delayed or ischemia-
uided PCI group (9.6% vs. 5.7%, p  0.064). When
ombining balloon and stent trials all together, there was a
onsignificant trend for a benefit for a systematic and early
CI as compared with a more conservative strategy. Ta
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October 3, 2006:1326–35 PCI Strategies After FibrinolysisAll the analyses for heterogeneity were nonsignificant for the
forementioned end points except for death and reinfarction
igure 3. (A) Systematic and early percutaneous coronary intervention
PCI) was associated with a nonsignificant reduction of death in the “stent
ra” studies as compared with ischemia-guided PCI (odds ratio, 0.56; 95%
onfidence interval [CI], 0.29 to 1.05; p  0.07; analysis for heterogeneity
as nonsignificant, p  0.71) whereas an increase in the rate of death was
bserved in the “balloon era studies” (odds ratio, 1.44; 95% CI, 0.69 to
.06; p  0.33; the analysis for heterogeneity was nonsignificant, p 
.74). The overall analysis showed a nonsignificant trend toward a
eduction of death in favor of systematic and early PCI (odds ratio, 0.83;
5% CI, 0.52 to 1.35; p  0.47; the analysis for heterogeneity was
onsignificant, p 0.41). (B) Systematic and early PCI was associated with
nonsignificant reduction of death or myocardial infarction in the “stent era”
tudies as compared with ischemia-guided PCI (odds ratio, 0.53; 95% CI, 0.33
o 0.83; p  0.0067; the analysis for heterogeneity was nonsignificant (p 
.95) whereas it was found to be detrimental in the “balloon era” studies (odds
atio, 1.76; 95% CI, 0.97 to 3.21; p 0.064; the analysis for heterogeneity was
onsignificant, p  0.74). The overall analysis showed a nonsignificant trend
oward a reduction of death or myocardial infarction in favor of systematic and
arly PCI (odds ratio, 0.85; 95% CI, 0.47 to 1.55; p 0.42). The analysis for
eterogeneity was significant (p  0.062). CAPITAL-MI  Combined
ngioplasty and Pharmacological Intervention Versus Thrombolytics Alone in
cute Myocardial Infarction; GRACIA-1  Randomized trial comparing
tenting within 24 h of thrombolysis versus ischemia-guided approach to
hrombolyzed acute myocardial infarction with ST-segment elevation; MA
meta-analysis; PTCA  percutaneous transluminal coronary angio-
lasty; SIAM Comparison of Invasive and Conservative Strategies After
reatment with Streptokinase in Acute Myocardial Infarction; TAMI 
hrombolysis and Angioplasty in Myocardial Infarction.hen combining balloon and stent trials (Figs. 3A and 3B). tacilitated PCI with fibrinolytic therapy. Four trials were
dentified, representing a total of 2,679 patients (Table 3)
6,33–35). The end points of death and reinfarction were
valuated separately because the combined end point was
ot available in any of the selected studies. The overall death
ate was 5.4%. Fibrinolysis-facilitated PCI was associated
ith a nonsignificant increase in the rate of death at 90 days
Fig. 4A). In addition, there was a 68% increase in the rate
f reinfarction in the fibrinolysis-facilitated PCI group
5.0%) as compared with the primary PCI group (3.0%, p
.013) (Fig. 4B). There was no significant increase in the
ate of major bleeding in the fibrinolysis-facilitated PCI
6.50% [80 of 1,230]) as compared with primary PCI (4.98%
62 of 1,243]) (OR, 1.23; 95% CI, 0.74 to 2.05; p  0.42).
ISCUSSION
he present study provides a series of answers regarding the
ptions facing the clinician caring for the patient with an
cute STEMI who underwent fibrinolytic therapy. It also
ighlights the relative paucity of data regarding this issue as
pposed to the experience accumulated in over 100,000 pa-
ients with fibrinolysis. First, our results suggest that all
atients with failed fibrinolysis, defined as a persistent chest
ain and/or nonresolution of ST-segment elevation 60 to 90
in after starting administration, should undergo catheteriza-
ion without delay. Second, our results also outline that
ystematic catheterization with stent-PCI performed within
4 h after thrombolysis is better than a noninvasive
atchful waiting strategy. Finally, fibrinolysis cannot be
ecommended as a facilitating strategy for PCI. Taken
ogether these findings highlight the need for a network
rganization to ensure rapid access to cardiac catheter-
zation facilities in regions where fibrinolysis is the main
ode of reperfusion.
The identification and management of failed fibrinolysis
as been the subject of much debate (36,37). A conservative
pproach has often been considered a pragmatic option,
articularly in hospitals without interventional facilities
38). Rescue PCI has also been shown to be feasible and safe
ore than 10 years ago, but the benefit has been questioned
39). A pooled analysis of randomized trials comparing
escue PCI to medical therapy during the “balloon era”
25–27) suggested a reduction in severe heart failure but
emained inconclusive for death or reinfarction (8) and did
ot provide clear guidance on whether rescue PCI should be
ystematically performed in patients with failed fibrinolysis.
wo recent studies (22–24) have readdressed this issue
iven the potential benefits of coronary stenting and new
harmacologic adjuncts. However, none of these studies
ere powered to assess the impact of rescue PCI on
ortality.
The first major finding of our meta-analysis is that
rescue angioplasty” after failed fibrinolysis improves sur-
ival as compared with a conservative approach. The mor-
ality benefit is mainly driven by the contemporary studies.
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PCI Strategies After Fibrinolysis October 3, 2006:1326–35hese studies have chosen more precise inclusion criteria
uch as failure of ST-segment resolution, which can identify
asily most failures with low false positives for patent
rteries (40) and with a good correlation to short-term
utcome (41). In addition, stent placement and concomitant
dministration of GP IIb/IIIa receptor antagonists may
ave greatly improved the results of rescue PCI. Indeed,
ost of the benefit on mortality was driven by REACT
Rescue Angioplasty Versus Conservative Therapy or Re-
eat Thrombolysis Trial), in which 69% of patients received
tent and 43% GP IIb/IIIa receptor antagonists. In the
igure 4. (A) Odds ratios for death within 90 days with fibrinolysis-
acilitated percutaneous coronary intervention (PCI) versus primary PCI
lone. Facilitated PCI had no significant impact on mortality. Overall odds
atios 1.30; 95% confidence interval (CI), 0.92 to 1.83; p  0.13. The
nalysis for heterogeneity was nonsignificant (p  0.46). (B) Odds ratios
or reinfarction within 90 days with fibrinolysis-facilitated PCI versus
rimary PCI alone. Facilitated PCI led to a significant increase in
einfarction. Overall odd ratios, 1.68; 95% CI, 1.12 to 2.51; p  0.013.
he analysis for heterogeneity was nonsignificant (p  0.46). ASSENT 
ssessment of the Safety and Efficacy of a New Treatment Strategy for
cute Myocardial Infarction; PACT  Plasminogen Activator-
ngioplasty Compatibility Trial; GRACIA-2  Primary Optimal Percu-
aneous Coronary Intervention versus Facilitated Intervention in STEMI
atients; MA  meta-analysis; PRAGUE  PRimary Angioplasty in
atients transferred from General community hospitals to specialized
TCA Units with or without Emergency thrombolysis.MERLIN (Middlesbrough Early Revascularisation toTa
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October 3, 2006:1326–35 PCI Strategies After Fibrinolysisimit Infarction) trial, PCI slightly increased survival but
learly improved event-free survival, mainly subsequent
evascularization. Only 50% of patients underwent stent
lacement, and 3% were given IIb/IIIa inhibitors in this
rial. As a consequence, there was no reduction in reinfarc-
ion as opposed to the REACT trial.
Systematic and early (24 h) PCI approach after admin-
stration of fibrinolysis irrespective of the latter’s success
ather than the traditional conservative approach of delayed
nd/or ischemia-guided PCI remains a controversial issue.
andomized trials performed during the “balloon era”
howed no benefit of a systematic mechanical strategy on
ard clinical end points (13,28,29,39). This strategy was
rogressively abandoned because of disappointing results
nd unacceptable bleeding. Contemporary studies have
ecently reassessed this hypothesis but were too small to
xamine mortality (30–32).
The present meta-analysis shows that early stent-PCI
fter fibrinolysis is associated with a better survival and a
ignificant reduction of death or reinfarction of STEMI
atients as compared with a delayed or ischemia-guided
CI strategy. These new findings draw the attention to the
eed for an appropriate network organization with adequate
mbulance systems, pre-hospital management, and well-
rganized catheterization laboratories as previously outlined
or transfer for primary PCI (3,42). Another important
oint is that PCI in the stent era trials was attempted with
delay of several hours after fibrinolysis initiation (Table 2).
p to 60% of patients randomized in the early PCI strategy
resented with TIMI flow grade 3 irrespective of the time
elay from fibrinolysis to angiography. Our data support the
dea that time delay required for transfer to the catheteriza-
ion laboratory after fibrinolysis may not be as critical as for
rimary PCI alone. Therefore, systematic catheterization
ithin 24 h after fibrinolysis may be feasible in the majority
f patients.
The benefits of these 2 PCI strategies after fibrinolysis
ere mainly observed in contemporary studies. It under-
cores the benefit of stenting in STEMI but also the critical
mpact of adjunctive pharmacology as stents have never been
hown to reduce mortality in the setting of primary PCI.
lthough GP IIb/IIIa inhibitors in combination with stent-
ng in primary PCI may save lives, their use was highly
ariable and overall low in the fibrinolytic studies chosen for
his meta-analysis (43–45). This reflects the lack of safety
ata on the use of GP IIb/IIIa inhibitors for post-
brinolysis PCI (43). However, the expected increase in
ajor bleeding observed with rescue PCI was offset by the
ortality benefit. The vast majority of bleeding events was
ocated at the arterial access site and could be avoided with
larger use of the radial approach (46). As opposed to
escue PCI, there was no excess of major bleeding in the
arly systematic PCI strategy after lysis. This may be due to
he longer delay between lysis and PCI as compared with descue PCI. Given the impressive benefit of rescue PCI and
he difficult task of identifying failed fibrinolysis, immediate
nd systematic routine angiography in patients with large
yocardial infarctions appears to be a reasonable recom-
endation.
Facilitated PCI is defined as a pharmacologic reperfusion
reatment administered before primary PCI to bridge the
elay between first medical contact and mechanical reper-
usion (47–49). Only 3 randomized studies have evaluated
his strategy against primary PCI alone (33–35), and the
fficacy of this concept remains unproven. Our analysis did
ot find any benefit of this strategy with a significant
ncrease of early infarction. Full-dose fibrinolysis was used
or facilitation except for PACT (Plasminogen Activator-
ngioplasty Compatibility Trial) (34). In the GRACIA-2
Primary Optimal Percutaneous Coronary Intervention ver-
us Facilitated Intervention in STEMI patients) trial, there
as also an important difference in the time delay between
andomization and catheterization between the 2 groups of
atients (32). The recent premature interruption of the
SSENT-4 (Assessment of the Safety and Efficacy of a
ew Thrombolytic Regimen-4) trial (35), opposing tenect-
plase (TNK)-facilitated PCI to primary PCI, goes, how-
ver, in the same direction. The significant excess of
einfarction related to early stent thrombosis in the TNK-
acilitated group suggests a deleterious prothrombotic effect
f fibrinolysis given immediately before PCI. This further
upports that fibrinolysis is not the ideal facilitating agent
or primary PCI. Glycoprotein IIb/IIIa receptor antagonists
educe ischemic events including mortality when used with
rimary PCI and in particular when given as facilitating
gents during transfer to the catheterization laboratory
43–45,50–52). The ongoing FINESSE (Facilitated Inter-
ention with Enhanced Reperfusion Speed to Stop Events)
rial will bring more information on this specific issue.
tudy limitations. Definitions of end points and the time
t which these were recorded may vary in the studies
ncluded for the meta-analysis. However, short of large
andomized trials adequately powered to look at end points
uch as mortality, meta-analyses such as this one provides an
lternative to examine these end points. Overlap of time
ntervals may exist between studies subgrouped into early
CI and facilitated PCI, which represents another potential
imitation. However, categorization of studies according to
he type of strategy rather than time window may be more
linically relevant. Finally, the different length of follow-up
mong studies is another limitation that cannot be ad-
ressed in the present meta-analysis.
In conclusion, our results support the concepts of rescue
CI for failed fibrinolysis and early (24 h) PCI regardless
f the success achieved after fibrinolysis. The safety of such
pproaches and the benefit of GP IIb/IIIa inhibitors in this
ontext warrant additional studies. Alternatively, fibrinolysis
oes not appear to facilitate PCI for STEMI (53,54).
R
I
s
F
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
1334 Collet et al. JACC Vol. 48, No. 7, 2006
PCI Strategies After Fibrinolysis October 3, 2006:1326–35eprint requests and correspondence: Dr. Gilles Montalescot,
nstitut de Cardiologie, Bureau 2-236, Centre Hospitalier Univer-
itaire Pitié-Salpêtrière, 47 Boulevard de l’Hôpital, 75013 Paris,
rance. E-mail: Gilles.montalescot@psl.aphp.fr.
EFERENCES
1. The GUSTO IIb Investigators. A comparison of recombinant hirudin
with heparin for the treatment of acute coronary syndromes. N Engl
J Med 1996;335:775–82.
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intra-
venous thrombolytic therapy for acute myocardial infarction: a quan-
titative review of 23 randomised trials. Lancet 2003;361:13–20.
3. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for
primary angioplasty versus immediate thrombolysis in acute myocar-
dial infarction: a meta-analysis. Circulation 2003;108:1809–14.
4. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus
fibrinolytic therapy in acute myocardial infarction. Am J Cardiol
2003;92:824–6.
5. Steg PG, Bonnefoy E, Chabaud S, et al., Comparison of Angioplasty and
Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM)
Investigators. Impact of time to treatment on mortality after prehospital
fibrinolysis or primary angioplasty: data from the CAPTIM randomized
clinical trial. Circulation 2003;108:2851–6.
6. Widimsky P, Groch L, Zelízko M, Aschermann M, Bednár F,
Suryapranata H, on behalf of the PRAGUE Study Group Investiga-
tors. Multicentre randomized trial comparing transport to primary
angioplasty vs immediate thrombolysis vs combined strategy for
patients with acute myocardial infarction presenting to a community
hospital without a catheterization laboratory. The PRAGUE Study.
Eur Heart J 2000;21:823–31.
7. Robinson KA, Dickersin K. Development of of highly sensitive search
strategy for the retrieval of of reports of controlled trials using Pubmed.
Int J Epidemiol 2002;31:150–3.
8. Ellis SG, da Silva ER, Spaulding CM, Nobuyoshi M, Weiner B, Talley
JD. Review of immediate angioplasty after fibrinolytic therapy for acute
myocardial infarction: insights from the RESCUE I, RESCUE II, and
other contemporary clinical experiences. Am Heart J 2000;139:1046–53.
9. Califf RM, Topol EJ, Stack RS, et al. Evaluation of combining
thrombolytic therapy and timing of cardiac catheterization in acute
myocardial infarction. Circulation 1991;83:1543–56.
0. Erbel R, Pop T, Diefenbach C, Meyer J. Long-term results of
thrombolytic therapy with and without percutaneous transluminal
coronary angioplasty. J Am Coll Cardiol 1989;2:276–85.
1. Rogers WJ, Baim DS, Gore JM, et al. Comparison of immediate
invasive, delayed invasive, and conservative strategies after tissue-type
plasminogen activator. Results of the Thrombolysis in Myocardial
Infarction (TIMI) phase II-A trial. Circulation 1990;81:1457–76.
2. Simoons ML, Arnold AER, Betriu A, et al., for the European
Cooperative Study Group for Recombinant Tissue-Type Plasminogen
Activator (rTPA). Thrombolysis with tissue plasminogen activator in
acute myocardial infarction: no additional benefit from immediate
percutaneous coronary angioplasty. Lancet 1988;331:197–203.
3. Topol EJ, O’Neill WW, Langburd AB, et al. A randomized, placebo-
controlled trial of intravenous recombinant tissue-type plasminogen
activator and emergency coronary angioplasty in patients with acute
myocardial infarction. Circulation 1987;75:420–8.
4. Guerci AD, Gerstenblith G, Brinker JA, et al. A randomized trial of
intravenous tissue plasminogen activator for acute myocardial infarc-
tion with subsequent randomization to elective coronary angioplasty.
N Engl J Med 1987;317:1613–8.
5. Özbek C, Dyckmans J, Sen S, Schieffer H, and the SIAM Study
Group. Comparison of invasive and conservative strategies after
treatment with streptokinase in acute myocardial infarction: results of
a randomized trial (SIAM) (abstr). J Am Coll Cardiol 1990;15:63A.
6. SWIFT Trial Group. SWIFT (Should We Intervene Following
Thrombolysis?) trial of delayed elective intervention versus conserva-
tive treatment after thrombolysis with anistreplase in acute myocardial
infarction. Br Med J 1991;302:555–60.7. Topol EJ, Califf RM, Vandormael M, et al., the Thrombolysis and
Angioplasty in Myocardial Infarction-6 Study Group. A randomizedtrial of late reperfusion therapy for acute myocardial infarction.
Circulation 1992;85:2090–9.
8. Williams DO, Braunwald E, Knatterud G, TIMI Investigators.
One-year results of the Thrombolysis in Myocardial Infarction Inves-
tigation (TIMI) phase II trial. Circulation 1992;85:533–42.
9. O’Neill WW, Weintraub R, Grines CL, et al. A prospective placebo-
controlled, randomized trial of intravenous streptokinase and angio-
plasty versus lone angioplasty therapy of acute myocardial infarction.
Circulation 1992;86:1710–7.
0. Clarke MOA. Cochrane Reviewer’s Handbook 4.2.0 (Updated March
2003). Oxford, UK: The Cokrane Library, 2003 (Issue 2).
1. Cucherat M, Boissel JP, Leizorovicz A, Haugh MC. EasyMA: a
program for the meta-analysis of clinical trials. Comput Methods
Programs Biomed 1997;53:187–90.
2. Gershlick AH, Stephens-Lloyd A, Hughes S, et al., REACT Trial
Investigators. Rescue angioplasty after failed thrombolytic therapy for
acute myocardial infarction. New Engl J Med 2006;353:2758–68.
3. Sutton AG, Campbell PG, Graham R, et al. One year results of the
Middlesbrough early revascularisation to limit infarction (MERLIN)
trial. Heart 2005;91:1330–7.
4. Sutton AG, Campbell PG, Graham R, et al. A randomized trial of
rescue angioplasty versus a conservative approach for failed fibrinolysis
in ST-segment elevation myocardial infarction: the Middlesbrough
Early Revascularization to Limit Infarction (MERLIN) trial. J Am
Coll Cardiol 2004;44:287–96.
5. Belenkie I, Traboulsi M, Hall C, et al. Rescue angioplasty during
myocardial infarction has a beneficial effect on mortality: a tenable
hypothesis. Can J Cardiol 1992;8:357–62.
6. Ellis SG, Riberiero da Silva E, Heyndrickx G, et al. Randomized
comparison of rescue angioplasty with conservative management of
patients with early failure of thrombolysis for acute anterior myocardial
infarction. Circulation 1994;90:2280–7.
7. Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective random-
ized comparison between thrombolysis, rescue PTCA, and primary
PTCA in patients with extensive myocardial infarction admitted to a
hospital without PTCA facilities: a safety and feasibility study. Heart
1999;82:426–31.
8. Belenkie I, Knudtson ML, Roth DL, et al. Relation between flow
grade after thrombolytic therapy and the effect of angioplasty on left
ventricular function: a prospective randomized trial. Am Heart J
1991;121:407–16.
9. The TIMI Research Group. Immediate versus delayed catheterization
and angioplasty following thrombolytic therapy for acute myocardial
infarction: TIMI II-A results. JAMA 1988;260:2849–58.
0. Le May MR, Wells GA, Labinaz M, et al. Combined Angioplasty and
Pharmacological Intervention versus Thrombolysis Alone in Acute
Myocardial Infarction (CAPITAL AMI trial). J Am Coll Cardiol
2005;46:417–24.
1. Scheller B, Hennen B, Hammer B, et al. Beneficial effects of
immediate stenting after thrombolysis in acute myocardial infarction.
J Am Coll Cardiol 2003;42:634–41.
2. Avilés FF, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy
within 24 hours of thrombolysis versus ischaemia-guided conserva-
tive approach for acute myocardial infarction with ST-segment
elevation (GRACIA-1): a randomised controlled trial. Lancet
2004;364:1045–53.
3. Avilés F. Grupo de Análisis de la Cardiopata Isquémica Aguda
(GRACIA-2). Presented at: European Congress of Cardiology; Vienna,
Austria: August 30–September 2, 2003.
4. Ross AM, Coyne KS, Reiner JS, et al., for the PACT Investigators. A
randomized trial comparing primary angioplasty with a strategy of
short-acting thrombolysis and immediate planned rescue angioplasty
in acute myocardial infarction: the PACT trial. J Am Coll Cardiol
1999;34:1954–62.
5. The ASSENT-4 PCI Investigators. Primary versus tenecteplase-
facilitated percutaneous coronary intervention in patients with ST-
segment elevation acute myocardial infarction: ASSENT-4 PCI ran-
domised trial (Assessment of the Safety and Efficacy of a New
Treatment Strategy with Percutaneous Coronary Intervention). Lan-
cet 2006;367:569–78.
6. Lavin F, Kane M, Forde A, Gannon F, Daly K. Comparison of five
cardiac markers in the detection of reperfusion after thrombolysis in
acute myocardial infarction. Br Heart J 1995;73:422–7.
33
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
1335JACC Vol. 48, No. 7, 2006 Collet et al.
October 3, 2006:1326–35 PCI Strategies After Fibrinolysis7. de Lemos JA, Morrow DA, Gibson CM, et al., for the TIMI 14
Investigators. Early non-invasive detection of failed epicardial reper-
fusion after fibrinolytic therapy. Am J Cardiol 2001;88:353–8.
8. Prendergast BD, Shandall A, Buchalter MB. What do we do when
thrombolysis fails? Int J Cardiol 1997;61:39–42.
9. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction
affect mortality and reinfarction rates? A quantitative overview (meta-
analysis) of the randomized clinical trials. Circulation 1995;91:
476 – 85.
0. Andrews J, Straznicky IT, French JK, et al. ST-segment recovery adds
to the assessment of TIMI 2 and 3 flow in predicting infarct wall
motion after thrombolytic therapy. Circulation 2000;101:2138–43.
1. de Lemos JA, Braunwald E. ST segment resolution as a tool for
assessing the efficacy of reperfusion therapy. J Am Coll Cardiol
2001;38:1283–94.
2. Gogbashian A. Transfer for primary angioplasty: time is important.
Circulation 2004;109:e175.
3. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as
adjunctive therapy to reperfusion in acute ST-segment elevation
myocardial infarction. A meta-analysis of randomized trials. JAMA
2005;293:1759–65.
4. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs
late administration of glycoprotein IIb/IIIa inhibitors in primary
percutaneous coronary intervention of acute ST-segment elevation
myocardial infarction: a meta-analysis. JAMA 2004;292:362–6.
5. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy
for acute myocardial infarction. J Am Coll Cardiol 2003;342:1186–9.
6. Philippe F, Larrazet F, Meziane T, Dibie A. Comparison of transra-
dial vs. transfemoral approach in the treatment of acute myocardialinfarction with primary angioplasty and abciximab. Catheter
Cardiovasc Interv 2004;61:67–73.
7. Gersh BJ, Stone GW, White HD, Holmes DR. Pharmacological
facilitation of primary percutaneous coronary intervention for acute
myocardial infarction: is the slope of the curve the shape of the future?
JAMA 2005;293:979–86.
8. Herrmann HC. Transfer for primary angioplasty: the importance of
time. Circulation 2005;111:718–20.
9. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous
coronary interventions. The task force for percutaneous coronary
interventions of the European Society of Cardiology. Eur Heart J
2005;26:804–47.
0. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein
IIb/IIIa inhibition with coronary stenting for acute myocardial infarc-
tion. N Engl J Med 2001;344:1895–903.
1. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein
IIb/IIIa receptor blockade with abciximab on clinical and angiographic
restenosis rate after the placement of coronary stents following acute
myocardial infarction. J Am Coll Cardiol 2000;35:915–21.
2. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in
patients with acute myocardial infarction undergoing primary angio-
plasty. Am J Cardiol 2002;90:533–6.
3. Polonski L, Gasior M, Wasilewski J, et al. Outcomes of primary
coronary angioplasty and angioplasty after initial thrombolysis in the
treatment of 374 consecutive patients with acute myocardial infarction.
Am Heart J 2003;145:855–61.
4. Zhang D, Cai X, Zhang R, Zhang J, Shen W. Primary intracoronary
stenting in comparison with intravenous rt-PA thrombolysis plus
rescue intracoronary intervention in patients with acute myocardial
infarction. Chin Med J 2002;115:163–5.
